Northwest Biotherapeutics (NWBO) Stock Moves in a Range: What to do Now?

The Northwest Biotherapeutics Inc (OTCMKTS:NWBO) stock did not have a great time in the markets last week but investors would be hoping for it to make a quick rebound this week.

Although there was no fresh news with regards to Northwest, the stock declined by as much as 10% and it might be worthwhile for investors to perhaps take a look at some of the developments from the recent past in order to get a better idea about the company. Last month there had been considerable optimism about the stock following speculation from investors that the company was all set to get a major breakthrough in the Phase III trial of its product DCVax®-L. The product is meant for treating some of the variants of cancers that are most resistant to treatments.

Many companies have tried and failed to come up with a solution in this regard and hence, speculation regarding the possibility of Northwest getting a breakthrough with DCVax®-L proved to be a major boost. In this regard, it should be noted that the company seemed to have indicated that the top-line data from the Phase III trial was highly positive and that, in turn, led to many investors piling on to the Northwest stock in a big way.

In addition to that, it is also necessary to note that DCVax®-L has also got considerable attention from the mainstream press and that is another factor behind the rising interest in Northwest stock among many investors. The decline last week could well be an anomaly.  

Regen BioPharma (RGBP) Stock Extends Jump on Heavy Volume: Are You Excited?

Those who are currently looking into major gainers in the biotech sector in recent days could consider taking a look at the Regen BioPharma Inc (OTCMKTS:RGBP) stock. This past week, the stock was in considerable focus among investors and managed to clock gains of as much as 51% through the week. The stock is up another 38% to $0.031 in the opening session on Tuesday.

The stock had really come into the attention of investors earlier this year in April when the company along with its subsidiary company KLS signed a licensing deal with Oncology Pharma Inc. As part of this agreement, Regen will be able to deploy some of the intellectual properties owned by Oncology Pharma for the development of treatments for pancreatic cancer. The licensing agreement is going to be in place for 15 years.

However, that is not all. There are certain other things that need to be kept in mind with regards to Regen BioPharma as well. At this point in time, the company is working on preparing its filings and eventually making the submissions so that it can get pink current status on the OTC Markets.

Once it gets that designation, the stock is expected to be even more attractive for many investors. The Regen stock has made a powerful move up the charts over the course of recent days and it is believed that it is on track to make similar moves that had been seen in some of the other micro-cap stocks like Tesoro and Enzolytics in recent months.

Skip to content